SCHEMBL25254014

SCHEMBL25254014

CC(C)(C)OC(=O)N1CC(c2ccc(-c3ccc(Cl)cc3F)cn2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.48
CYP3A4 P08684 2/20 0.45
CYP3A5 P20815 2/20 0.45
ALOX5AP P20292 3/20 0.42
FEN1 P39748 3/20 0.42
GPR119 Q8TDV5 4/20 0.41
RET P07949 1/20 0.40
PIK3CA P42336 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
BACE1 P56817 1/20 0.40
CACNB4 O00305 1/20 0.40
CACNA1A O00555 1/20 0.40
CACNA1G O43497 1/20 0.40
CACNG3 O60359 1/20 0.40
CACNA1F O60840 1/20 0.40
CACNA1H O95180 1/20 0.40
CACNB3 P54284 1/20 0.40
CACNA2D1 P54289 1/20 0.40
CACNG7 P62955 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29497054 1.00 USP30 (0.48) USP30CYP3A4CYP3A5ALOX5APFEN1
SCHEMBL25254039 0.90 RET (0.43) USP30ALOX5APFEN1RETPIK3CA
SCHEMBL29497024 0.90 RET (0.43) USP30ALOX5APFEN1RETPIK3CA
SCHEMBL25296990 0.89 USP30 (0.48) USP30CYP3A4CYP3A5ALOX5APFEN1
SCHEMBL25290176 0.86 GPR119 (0.42) USP30GPR119RETPIK3CA
SCHEMBL29497025 0.86 GPR119 (0.42) USP30GPR119RETPIK3CA
SCHEMBL25297814 0.85 USP30 (0.51) USP30CYP3A4CYP3A5GPR119CNR1
SCHEMBL25252769 0.84 FASN (0.44) ALOX5APFEN1CNR1FASN
SCHEMBL21381749 0.83 MEN1 (0.48) USP30ALOX5APFEN1MEN1KMT2A
SCHEMBL30567976 0.83 MEN1 (0.48) USP30ALOX5APFEN1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119301113-A Novel heterocyclic carbonyl cyclic compounds as MAGL inhibitors 豪夫迈·罗氏有限公司 2025-01-10 CN disclosed
US-11981661-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2024-05-14 US disclosed
EP-4208456-A1 HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2023-07-12 EP disclosed
CN-115989228-A Heterocyclic compounds 豪夫迈·罗氏有限公司 2023-04-18 CN disclosed
US-20220098176-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2022-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220098176-A1 HETEROCYCLIC COMPOUNDS CBR3, BRIX1, CCNY USP30 3722/4885CYP3A4 51/4885CYP3A5 64/4885
US-11981661-B2 Heterocyclic compounds CBR3, BRIX1, CCNY USP30 3722/4885CYP3A4 51/4885CYP3A5 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.